Question 1

What is peptide therapy, and who decides what it covers?

Accepted Answer

Peptide therapy is the name clinics and online storefronts use for giving someone a peptide. It is not a term of art in pharmacology and it is not a licensing category, which means anyone selling anything may print it on a door. The underlying chemistry is extremely broad: a 2026 primer for orthopaedic and sports medicine physicians describes therapeutic peptides as short-chain amino acids that regulate cellular functions and facilitate biochemical processes. On that definition insulin is a peptide therapy, and so is a vial bought from a website that calls its contents research material. The primer was written because the commercial side had grown quickly, recording significant growth in the global market for therapeutic peptides and thus its popularity among patients. That growth is the thing the phrase actually names. So the question worth asking is never what peptide therapy is in general, but which molecule, in which product, with which record standing behind it.

Question 2

Is peptide therapy a category a regulator recognises?

Accepted Answer

No regulator licenses the phrase, and that is the most useful single fact on this page. Regulators approve products rather than categories, and each approval names one molecule, one condition and one group of people. Nothing in that machinery can grant a licence to a word. A 2026 review in sports medicine put the state of play bluntly, noting that clinical adoption has outpaced high-quality evidence and regulatory consensus. Its conclusion drew the line where the approvals sit: clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols. Read that slowly, because it is narrower than it looks. It means approved drugs, used only for what they were approved for. A clinic that offers peptide therapy may be inside that line, well outside it, or selling a menu with both on it. The words on the door do not tell you which.

Question 3

Which compounds actually get sold under the name?

Accepted Answer

The reviews written for clinicians name much the same short list, which makes them a fair guide to what a menu tends to hold. The 2026 orthopaedic primer searched the literature on the most popular injectable types, and the key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. A 2026 review of regenerative peptides in pain medicine covered an overlapping set that added collagen peptides and cibinetide to the same group of repair compounds. A third strand is the growth hormone axis, where a 2026 endocrinology review reported that the agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues, alongside the secretagogues and the IGF-1 analogues. Notice what those three lists have in common. One name among them carries an approval, for a condition almost nobody is buying it for, and the remainder carry none at all. Each compound that recurs has a page of its own on this site, which is where the evidence for it belongs.

Question 4

What are approved peptide medicines used for?

Accepted Answer

The approvals that do exist map out a field that looks very little like a wellness menu. Tesamorelin was approved by the Food and Drug Administration in November 2010 for lipodystrophy — a change in the way the body stores fat — in people with HIV. Bremelanotide is FDA-approved for a sexual desire disorder in premenopausal women, and that is the whole of what it covers. Teduglutide and recombinant growth hormone are now approved for clinical use in patients with short bowel syndrome. The weight-loss group is the one that made the phrase famous: six medications are currently approved by the US Food and Drug Administration for long-term use, and three of them are peptides. Read down that list and the shape of it is clear. Most of it is rare-disease care, tied to a named diagnosis and a small group of people. None of it is an approval for a word on a door. Whether being a peptide makes a compound like Ozempic is taken apart on the safety overview.

Question 5

Is this a new field, or an old one with a new shopfront?

Accepted Answer

Peptide medicine itself is not new, and the pace of it is the opposite of a menu. Injectable recombinant human IGF-1, sold as mecasermin, has been available for nearly 20 years for treatment of the rare instances of GH insensitivity, which is one inherited cause of growth failure rather than a general tonic. New approvals then arrive in very small numbers each year. In 2025, the FDA approved 46 novel drugs, including four TIDEs — the industry shorthand for peptides and oligonucleotides. Only one of those four was a peptide, and elamipretide further expanded this paradigm by becoming the first disease-specific treatment approved for Barth syndrome, an inherited condition affecting the heart and skeletal muscle. A field that adds roughly one approved peptide a year, each tied to a named disease and arriving after years of trials, is a slow and narrow thing. The shopfront is the part that is new.

Question 6

Does an approval travel to a compounded or research-grade vial?

Accepted Answer

It does not, and this is the most load-bearing distinction anyone reading about peptide therapy has to hold. An approval attaches to a particular product, made to a particular standard and sold with a particular label, and the trial record that earned the approval was generated using that product. Change the manufacturer and the label does not come along with the molecule. Both halves of this appear in the literature. A 2024 pilot study set out to assess the safety and efficacy of BPC-157 manufactured by a 503A compounding pharmacy as a treatment for interstitial cystitis, a compounded version of a compound the same paper describes as currently not approved by the US Food and Drug Administration. A 2018 analysis of falsified biotechnology drugs reported that multiple reports have namely described the presence of the wrong active pharmaceutical ingredient (API), the wrong dosage or the absence of the API. So an approved schedule describes an approved product. It says nothing about what is inside an unlabelled vial, and the checks that can actually be run on one are worked through at the sourcing overview.

Question 7

How far apart are the strongest and weakest things sold under the name?

Accepted Answer

Very far apart, and one review set out to measure the distance. A 2026 endocrinology review of performance peptides sorted the field, stratifying peptides into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies. Both ends of that range turn up on the same menu. At the strong end sit the weight-loss drugs. A 2026 sports medicine review found that glucagon-like peptide-1 receptor agonists are the only class supported by reproducible randomized evidence of symptomatic improvement in knee osteoarthritis. At the other end sits BPC-157, where the orthopaedic primer reported a single human case series, and noted that significant methodological flaws and a lack of controls limit its applicability and reliability. One of those is a repeat result in a named condition. The other is one uncontrolled series with nothing to compare it against. Average the two into one view of peptide therapy and you throw away the only thing worth knowing. What each compound has behind it, outcome by outcome, is gathered at the researched-effects overview.

Question 8

What do doctors think about peptides?

Accepted Answer

Several of these reviews were written by clinicians for clinicians, which is about as close to an answer as the literature gets. The 2026 orthopaedic primer is blunt about it. It states that it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. The 2026 sports medicine review lands in the same place. It holds that clinicians caring for athletes must counsel patients regarding uncertain efficacy, product quality, safety risks, and antidoping implications. A 2026 endocrinology review goes a step further and builds a tool for the clinic room. It sets out an assessment algorithm to support exposure history taking, triage of symptom domains, and risk communication without legitimising off-label peptide regimens. Read the three together and one pattern shows through. The professional literature is not telling doctors to refuse the subject. It is telling them to expect patients who already use these compounds, and to know what to look for.

Question 9

Is the clinical position settled, or argued over?

Accepted Answer

It is argued over, and the argument is worth seeing, because it cuts both ways. A 2026 review of peptide therapies in thyroid medicine found that available data consist primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports. It concluded that clinical use remains largely investigational in the context of thyroid disease. That is the cautious majority view, and most of the reviews gathered for this page sit near it. Pushing the other way is a 2024 review of thymosin alpha 1, drawing on more than thirty trials. It objected to a regulatory decision head on, writing that contrary to the FDA's restriction on Tα1 and 21 additional peptides in 2023, its own analysis found consistent evidence. It went on to urge that the FDA permits 503A compounding pharmacies to compound Tα1. A reader can hold both of those at once. The evidence behind most of these compounds is thin, and at least one restriction is disputed by people who have read the trials.

Question 10

Why does this page name no clinic?

Accepted Answer

Because a clinic is a business, and the research gathered for this page is about molecules. Nothing in it rates a provider, compares one practice against another, or establishes that any particular premises handles this material competently. The only clinics these sources describe at all are study settings: the BPC-157 pilot records that twelve women between the ages of 39 and 76 years with a mean age of 58.3 years participated in this trial at a private clinic, which tells a reader where twelve people were given an injection and nothing whatever about anywhere else. There is also a plain conflict problem underneath the question. A page that recommends a seller acquires an interest in what it then says about the evidence, and the entire value of a reference is that it holds no such interest. What can honestly be checked about a supplier — registration, laboratory reports, enforcement history — is worked through at the sourcing overview.

Question 11

How much does peptide therapy cost?

Accepted Answer

There is no answer to that question as asked, and the one priced course among these sources shows exactly why. Increlex is the branded form of mecasermin, approved for a rare disorder of childhood growth, and because a public drug plan assessed it the arithmetic was published in full: treatment with Increlex is expected to cost approximately $183,416 per patient per year, assuming an average patient weight of 14.1 kg. The same assessment concluded that Increlex does not represent good value to the health care system at the submitted price and requires at least a 92% price reduction. That figure belongs to one molecule, one diagnosis and one weight-based schedule, and it transfers to nothing else whatsoever. Grey-market vials are priced by whoever happens to be selling them, and none of the sources covered here records what any of them charge. This page therefore quotes no monthly figure for a course, because any figure it quoted would be an invention rather than a measurement.

Question 12

Is peptide therapy covered by insurance?

Accepted Answer

Coverage follows an approval and a diagnosis. It never follows a category. The clearest worked example among these sources is Increlex again, where a public drug plan spelled out what cover turns on. The conditions it set for patients name the prescriber and the price: Increlex should only be reimbursed if prescribed by a pediatric endocrinologist, if it is not prescribed in combination with recombinant growth hormone treatment, and the price of Increlex is reduced. Who could get it was narrower still. The rule was limited to patients at least 2 years of age with confirmed diagnosis of SPIGFD and in whom epiphyseal growth plates have not yet closed, meaning the growth plates at the ends of the long bones. Three conditions, one kind of prescriber, one rare disease. Nothing of that shape exists for a compound with no approval at all, and none of the research behind this page describes a payer paying for one. So the honest answer has two halves. Some peptide medicines are covered, for the people the approval names, and the rest sit outside the system completely.

Question 13

Is there a set schedule for a course of peptide therapy?

Accepted Answer

Not for most of what is sold under the name, and the orthopaedic primer says so in a single sentence: importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. That sentence is about the popular injectable compounds, and it covers four separate things a reader would need before a course could mean anything at all. Where a product is approved the opposite holds, because the schedule is part of what was submitted, tested and then licensed. A 2024 randomised trial compared tesamorelin against identical placebo in people with HIV, and the result of that trial belongs to its schedule rather than to the molecule in the abstract. Which is the distinction worth carrying away: a schedule is a finding about a product, not a property of a peptide. The amounts and intervals that appear in the published studies are catalogued at the dosing overview, and what an injection involves in practice is covered at the peptide injections overview.

Question 14

What does bundling all of this under one word do to a reader?

Accepted Answer

It lets a strong record stand in for a weak one. A 2026 review of regenerative peptides in pain medicine makes the dependency explicit, noting that because most of these therapies remain unapproved by the U.S. Food and Drug Administration (FDA) and clinical evidence in humans is limited, their use should be guided by careful clinical judgment. That sentence only does any work compound by compound. Collapse it into a category and the caution attaches to nothing in particular, which is precisely the effect a menu produces. The same move runs in the other direction with risk. A 2026 endocrinology review wrote of the absence of regulatory approval for physique- or performance-related indications and the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. Uncertainty about what is inside a vial is not a property of peptides. It is a property of a supply chain, and it does not divide along the lines the word quietly suggests.

Question 15

What would have to change before the phrase meant something?

Accepted Answer

The reviews are unusually specific about this, and they all ask for the same thing. The orthopaedic primer closes by saying that significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients. A 2026 review of peptides in ageing puts it in its own words. It holds that investigational peptides require rigorous validation through well-designed clinical trials. The thyroid review asks for well-designed thyroid-focused clinical trials to clarify safety, efficacy, and appropriate clinical roles. Three fields, three papers, one request. What they want is a trial in the people the compound is being sold to. That last part is the one that keeps getting skipped. A trial in people with HIV-related fat redistribution is a real trial and a real result. It is still not a result about a healthy thirty-year-old who bought the same molecule for a bad knee.

Question 16

How should a reader approach a menu that uses this phrase?

Accepted Answer

Four questions turn the phrase back into something checkable, and every one of them has an answer that can be looked up rather than guessed. The first is which molecule it actually is, named as a molecule rather than as a brand or a blend. The second is whether that exact molecule carries an approval anywhere, and if it does, for which condition and which population. The third is whether what is on offer is the approved version or a compounded or research-grade one, because the record belongs to the first and not to the second. The fourth is what was measured for that molecule, in whom, how many of them, and against what comparison. A menu that can answer all four is describing medicine, and a menu that can answer none of them is describing a word. The same caution appears in the literature itself, where the thyroid review closes by calling peptide therapeutics a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation. Where peptides sit next to steroids, proteins and SARMs is worked out on the comparisons overview, and what has been recorded as harm, one compound at a time, lives on the safety overview.

Peptide therapy: what the word covers